Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Scemblix Global Growth in Constant Currencies by Quarter
Scemblix Global Growth in Constant Currencies (% cc) (%)
Novartis Scemblix Global Growth in Constant Currencies: 67.0% in Q3 2026, down 28.0 pts from a year earlier.
Latest, Q3 2026
67.0%
Period ended Sep 30, 2026
Change on a year earlier
-28.0 pts
95.0% in Q3 2025
History
15 quarters
Since Q1 2023
Sources
15
Documents cited below
Where the Q3 2026 figure comes from
“|| Scemblix | 593 | 358 | 66 | 67”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Scemblix Global Growth in Constant Currencies (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.